综述

糖尿病性视网膜病变抗血管内皮生长因子治疗进展

展开
  • 上海交通大学附属第一人民医院眼科, 上海 200080
王莉莉(1986—), 女, 博士生;电子信箱: lilywang_ophthal@163.com。

网络出版日期: 2012-02-28

基金资助

上海市眼底病重点实验室开放课题基金(07Z22911)

Update on anti-vascular endothelial growth factor therapy for diabetic retinopathy

Expand
  • Department of Ophthalmology, the First People's Hospital, Shanghai Jiaotong University, Shanghai 200080, China

Online published: 2012-02-28

Supported by

Shanghai Key Laboratory for Ocular Fundus Diseases Foundation, 07Z22911

摘要

血管内皮生长因子(VEGF)在糖尿病性视网膜病变(DR)发病过程中的重要作用逐渐得到广泛而深入的认识。阻断VEGF信号转导通路上的任何环节即可抑制VEGF发挥其生物学特性,从而达到治疗目的。文章以治疗DR的抗VEGF药物的不同作用位点为分类依据,对目前处于临床或实验室研究阶段的各类药物的机制和疗效等进行综述。

本文引用格式

王莉莉, 刘 堃, 许 迅 . 糖尿病性视网膜病变抗血管内皮生长因子治疗进展[J]. 上海交通大学学报(医学版), 2012 , 32(2) : 219 . DOI: 10.3969/j.issn.1674-8115.2012.02.021

Abstract

A comprehensive consensus has been reached that vascular endothelial growth factor (VEGF) plays an important role in the pathogenesis of diabetic retinopathy (DR). Theoretically, a block to any step of the VEGF signal pathway may interrupt the biological function of VEGF, so that the therapeutic effect can be achieved. This paper reviews the mechanisms and efficacies of different anti-VEGF drugs, either in clinical trial or laboratory research phase, that have been used in the treatment of DR.

文章导航

/